US-Investment

Bayer Crop Science Plans to Invest Close to US$ 1 Billion in the US Market

Page: 2/3

Related Companies

The new West Sacramento site, which also serves as the global headquarters of Bayer CropScience’s Biologics Business, has the capacity to house up to 300 employees. The approximately US$ 80 million facility is situated on 10 acres of land and features a 100,000-square-foot building and a 35,000-square-foot pilot plant to support research and development of biological crop protection products, as well as a 30,000-square-foot Vegetable Seeds research building. The facility will also include a 2,000-square-foot greenhouse and five acres of nearby land for future greenhouse space.

Expansion of production capacities in the USA

In addition to building its R&D network in the United States, Bayer CropScience is also investing significantly in the production capacities of its crop protection products.

“Along with capacity expansions at our Muskegon, Michigan and Kansas City, Missouri sites, the construction of our new plant in Mobile, Alabama for the production of our herbicide Liberty™ will contribute significantly to our future growth plans,” stressed Condon, who pointed out that the increased production of Liberty™ will help U.S. growers fight weed resistance, a key challenge for U.S. farmers.

“The single biggest investment item in the USA is our planned capacity expansion of Liberty™ herbicide. This is a strong signal to the market as Liberty™ is the only non-selective herbicide that controls glyphosate resistant weeds," said Jim Blome, president and CEO for Bayer CropScience LP and Head of Crop Protection for the North American region.

“Two-thirds of our planned investments in the United States between 2013 and 2016 are intended to expand our production capacities. This includes measures to further optimize our supply chain in order to increase flexibility and thrive despite market volatility,” Blome added.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent

(ID:42932699)